Oftensin, 2.5 mg/ml, eye drops, solution
Timolol
The active substance of Oftensin is timolol. Timolol belongs to a group of medicines called beta-blockers.
Timolol lowers the pressure in the eye by reducing the production of aqueous humor in the eye and increasing its outflow through the uveoscleral tract. Timolol also has a slight effect on episcleral venous pressure.
The medicine does not affect the pupil size or accommodation, which does not disturb vision.
The effect of the medicine starts about 10-30 minutes after administration, and the maximum decrease in intraocular pressure occurs after 1-2 hours. The effect of the medicine lasts up to 24 hours after a single dose.
Indications for use are:
Before starting treatment with Oftensin, discuss with your doctor the following situations:
Risk of anaphylactic reaction
During treatment with timolol, patients with atopic disease or a history of severe anaphylactic reactions to various allergens may exhibit an increased reaction to repeated exposure to these allergens, both accidental and during diagnostic or therapeutic procedures. These patients may not respond to the usual doses of adrenaline used to treat anaphylactic reactions.
Anesthesia during surgical procedures
Before surgical anesthesia, inform your doctor about the use of Oftensin, as timolol may affect the action of some anesthetics.
Timolol in the form of eye drops should be used with caution in children and adolescents. In newborns, infants, and small children, timolol should be used with special caution. If coughing, wheezing, abnormal breathing, or abnormal pauses in breathing (apnea) occur, the use of the medicine should be stopped immediately. Contact your doctor as soon as possible. A portable monitor to control apnea may be useful.
Timolol has been studied in infants and children aged 12 days to 5 years who had elevated intraocular pressure or were diagnosed with glaucoma. For more detailed information, consult your doctor.
Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
Oftensin may affect the action of other medicines or its action may be changed by other medicines, including other eye drops used to treat glaucoma. Inform your doctor if you are using or plan to use medicines that lower blood pressure, heart disease medicines, or diabetes medicines.
Some medicines should not be used at the same time as timolol, and in other cases, your doctor may recommend a change in dosage.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine.
Do not use the medicine during pregnancy unless your doctor decides it is necessary.
Do not use the medicine during breastfeeding, as timolol may pass into breast milk.
While using timolol in the form of eye drops, visual disturbances and dizziness may occur, which can affect your ability to react. If you experience such side effects, do not drive or operate machinery.
The medicine contains 0.12 mg of benzalkonium chloride per 1 ml of solution.
Benzalkonium chloride may be absorbed by soft contact lenses and change their color. Remove contact lenses before administration and wait at least 15 minutes before putting them back on. If you have an eye infection, it is not recommended to wear contact lenses.
Benzalkonium chloride may also cause eye irritation, especially in people with dry eye syndrome or disorders affecting the cornea (the transparent layer on the front of the eye). If you experience any abnormal sensations, stinging, or pain in the eye after using the medicine, contact your doctor.
Oftensin 2.5 mg/ml contains 12.72 mg of phosphates per 1 ml of solution.
Oftensin 5 mg/ml contains 11.78 mg of phosphates per 1 ml of solution.
In patients with severe damage to the transparent, anterior part of the eye (cornea), phosphates may rarely cause corneal clouding due to calcium deposits during treatment.
Timolol is well tolerated by patients using hard contact lenses made of polymethylmethacrylate (PMMA).
Always use this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Before recommending the use of timolol, the doctor should perform a thorough medical examination. The doctor will carefully assess the risk-to-benefit ratio of using timolol.
If the benefits outweigh the risks, the medicine should be administered at the lowest available concentration once a day.
In children, a 0.1% solution is usually sufficient to lower intraocular pressure. If this dose does not sufficiently lower intraocular pressure, it may be necessary to administer the medicine twice a day with a 12-hour interval. Children, especially newborns, should be closely monitored for 1 to 2 hours after the first dose and closely monitored for side effects until the surgical procedure is performed.
Treatment period
In children and adolescents, the medicine is used for transitional treatment.
Recommended dose of the medicine for adults
Initially, one drop of Oftensin 2.5 mg/ml solution into each affected eye twice a day.
If the treatment result is insufficient, the doctor will recommend using one drop of Oftensin 5 mg/ml solution into each affected eye twice a day.
Intraocular pressure should be regularly monitored.
To lower intraocular pressure, Oftensin can be used with other medicines. However, it is not recommended to use two topical beta-blockers at the same time (see section 2. Important information before using Oftensin).
Since in some patients, stabilization of intraocular pressure occurs only after several weeks of treatment with timolol, the assessment of the medicine's effect should be based on intraocular pressure measurements after about 4 weeks of use.
In many cases, if intraocular pressure is stabilized, the doctor may reduce the dose of the medicine, recommending its use once a day.
If you have been using another beta-blocker eye drop previously, you should use the usual dose on the last day of its use. The next day, stop the previous medicine and use Oftensin 2.5 mg/ml - one drop into each affected eye twice a day. If the treatment result is not satisfactory, the doctor may increase the dose to one drop of Oftensin 5 mg/ml into each affected eye twice a day.
If you have been using another anti-glaucoma medicine that is not a beta-blocker, you should continue using it on the same day, adding one drop of Oftensin 2.5 mg/ml into each affected eye twice a day. The next day, stop the previously used anti-glaucoma medicine and continue treatment with Oftensin.
If a higher dose of the medicine is necessary, the doctor will recommend using one drop of Oftensin 5 mg/ml into each affected eye twice a day.
Eye drop solutions may become contaminated with bacteria if not stored and used properly, causing eye infections. Using contaminated solutions can lead to serious eye damage and vision loss.
If you use a higher dose of the medicine than recommended, contact your doctor immediately, who will provide appropriate treatment.
Symptoms of overdose may include: decreased blood pressure, slowed heart rate, bronchospasm, and acute heart failure.
If you miss a dose of the medicine, take it as soon as possible. However, if it is almost time for the next dose, do not take the missed dose. Do not take a double dose to make up for the missed dose.
If you have any further questions about using this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Oftensin eye drops are generally well tolerated.
Like other locally used eye medicines, timolol is absorbed into the bloodstream. It may cause the same types of side effects as intravenously or orally administered beta-adrenergic blockers. The frequency of systemic side effects after topical administration to the eye is lower than after oral administration or injection.
*frequency not known (frequency cannot be estimated from available data)
Other side effects reported in connection with the use of eye drops containing phosphates
In patients with severe damage to the transparent, anterior part of the eye (cornea), phosphates may rarely cause corneal clouding due to calcium deposits during treatment.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep this medicine out of the sight and reach of children.
Store in a temperature not exceeding 25°C, protected from light.
Shelf life after first opening the container: 28 days.
Do not use this medicine after the expiry date stated on the packaging after: EXP.
The expiry date refers to the last day of the specified month.
The inscription on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot means the batch number.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The pack contains 5 ml of solution.
Polpharma S.A.
Pelplińska 19, 83-200 Starogard Gdański
Phone: +48 22 364 61 01
Polfa Warszawskie Zakłady Farmaceutyczne S.A.
Karolkowa 22/24, 01-207 Warsaw
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.